Publication: 2536

NCCTG N0543 (Alliance): A Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
      QxMD      Google Scholar   
Citation:
Cancer vol 123 (18) 3494-501
Year:
2017
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
7
Parents:
818  
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
Sanofi-Aventis, Pfizer  
Grants:
U10 CA180821, U10 CA180882, U10 CA180790  
Corr. Author:
 
Authors:
                         
Networks:
LAPS-MN026, METROMIN   
Study
NCCTG-N0543
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: